|
Comparing EDTA I.V. Chelation and TriCardia+
Basically, the only advantage of I.V. administered EDTA over that
of oral administration is that of initial speed. I.V. EDTA will
immediately enter the bloodstream whereas orally administered
EDTA will take at least 20 minutes to an hour before EDTA will
be fully absorbed, as the gut will buffer the amounts of EDTA
entering the bloodstream, ensuring a slow and even assimilation.
(Please note: Oral administration of EDTA is, in fact, much like
the slow and even assimilation provided by the drip of an I.V.
administration; it just takes a few minutes longer to get into
the bloodstream.)
Also I.V.
administration will ensure that EDTA will not be used for other
purposes in the body and will be primarily available for immediate
chelation in the circulation. However, within 30 minutes (and
perhaps sooner), I.V. chelated EDTA will begin to circulate to
other areas of the body wherein molecular competition (similar
to that of orally consumed EDTA) will be experienced. Other than
that, there is no known nor scientifically proven advantage of
I.V. administered EDTA over that of orally administered EDTA.
Thus, as is
with other Free Form Amino Acids, when EDTA is taken orally, it
should be with other Free Form Amino Acids to ensure that biochemical
competition (such as transamination occurring within the liver)
is minimized and reduced, not only upon consumption, but later
within the bloodstream, so as to keep EDTA populations in Free
Form and at a maximum. Indeed, for this very reason, I.V. formulas
could be improved greatly with the addition of other Free Form
Amino Acids.
TriCardia+
can be used safely with I.V. Chelation, as an additional agent
of chelation as well as to provide additional help of buffering
the body from chelation results. But,
TriCardia+ has additional
benefits offered over and above I.V. Chelation alone, namely the
detoxifying of the liver and kidneys. Normal I.V. Chelation does
not cleanse the liver or the kidneys, the filters of the cardiovascular
system, whereas TriCardia+ does.
Despite the
power of EDTA I.V. Chelation, it is only effective in removing
some (not all) heavy metals from the bloodstream. EDTA is most
attracted to metals and heavy ionic metallic minerals which have
a double valency, such as lead and calcium. I.V. Chelation does
not and will not remove all toxic elements and metals from the
cardiovascular system.
However, TriCardia+
offers not only safe amounts of EDTA, but 31 Free Form Amino Acids
(e.g. L-Cysteine) which help chelate other excess toxic metal
possibilities such as nickel, tin, zinc and copper more efficiently
from the system. L-Glutathione in particular alters the action
of dangerous peroxides, and has also been recently shown to be
an effective agent against the HIV-1 virus, as well as help in
removing dangerous excesses of homecysteine from the body. In
general, most I.V. Chelation formulas are not as sophisticated
nor as broad a spectrum as
TriCardia+ and do not have the elements
which would create such safety and power. Furthermore, the additional
nutraceuticals in TriCardia+
help the body rid itself of toxins
faster and more efficiently than I.V. Chelation alone.
EDTA I.V.
Chelation is only effective in removing free (not bound or attached)
heavy metals and minerals from the bloodstream. It cannot, and
will not, ever breakdown or dissolve cholesterol-calcified plaque
as some imagine. By itself, it is useless against the cholesterol
plaque already formed and lining the veins and arteries of our
cardiovascular system. The reason is that EDTA as a chelating
agent can only attach itself to unattached or free metals and
minerals in the bloodstream. EDTA cannot attach itself to the
calcium or lead which is bound to the walls of veins or arteries.
But unlike I.V. Chelation, TriCardia+
contains a complex of buffering
agents, safe and all natural ingredients, which by themselves,
have been shown to help the body naturally dissolve calcified
acidic plaque. Once dissolved, the chelating agents found within
TriCardia+ can then naturally grab onto the now freed metals and
minerals, removing them safely from the cardiovascular system.
This breakdown of plaque can be increased by further buffering
with other alkalizing agents, such as those found within Växa's
Buffer-pH+. It is known that by decreasing systemic acidic
values, calcification can be slowly and safely dissolved over
time.
Although I.V.
administered EDTA can help kidney function by removing heavy metals,
and thus indirectly increase the efficiency of circulation and
ionic distribution within the kidney, it does not address other
nutritional support problems of the kidneys and liver as does
TriCardia+. The other natural ingredients within TriCardia+, along
with EDTA, will similarly help the body to naturally improve circulation
and ionic balance within the kidneys. But TriCardia+ contains
specific phytomedicinals, which ingredients by themselves have
been shown to help the body quickly and effectively dissolve calcified
stones and other toxic and unhealthy debris which may collect
within the kidneys (and the gall bladder), while detoxifying the
liver, allowing these materials to harmlessly and painlessly pass
from the system as well. I.V. Chelation formulas do not offer
this advantage.
Lastly, TriCardia+
contains a chorded blend of micro-nutritionals and glycosaminoglycans
which possess natural abilities to specifically help the body
to regenerate and heal the overly stressed, traumatized and damaged
tissues of the cardiovascular system, liver and kidneys. I.V.
Chelation has little, if any, initiatory nutritional support powers
of cellular regeneration.
The result
is that due to the additional strengths of TriCardia+, which are
not offered by I.V. Chelation alone, many Chelationists are now
successfully complementing I.V. Chelation Therapies (which have
a limited range of activity) with the Oral Chelation and Detoxifying
powers of TriCardia+.
Dosage
of EDTA in TriCardia+
A full daily dose of TriCardia+ (12 capsules) contains 1.5 grams
of EDTA, buffered within a combination of 31 other Free Form Amino
Acids and other buffering compounds, as well as the full spectrum
of mineral ascorbates, phytomedicinals and free radical and heavy
metal scavengers.
The Results
of Oral and I. V. Chelation
Appropriate
buffered Chelation, which not only removes heavy metals from the
body, but helps in the dissolution of calcified plaque within
the cardiovascular system should, overtime, improve circulation
tremendously. Both Oral and I.V. Chelation seem very effective,
and may have synergistic results when used together. Remember,
chelation by itself is a process which is a natural function of
the body systemically. Increasing the population of chelating
agents, either by oral or I.V. means, can only enhance the effectiveness
of chelation in the long run.
Medical texts
estimate that an increase in just 1mm in diameter of the lumen
within veins and arteries will permit a 4-fold increase in blood
flow! Such an increase allows fresh oxygenated blood and nutrients
to efficiently feed all the cells of the body, as well as aid
in the speedy removal of all waste products coming from those
cells. Such a cleansing can aid in the recovery and treatment
of a number of diseases including:
1-
Cardiovascular Disease (including Arteriosclerosis, Heart Attack,
Stroke, High Cholesterol, High Blood Pressure)
2-
All Forms of Cancer
3-
Diabetes and Obesity
4-
Neurological diseases including MS, MD, ALS and Parkinson's
5-
Liver and Kidney disease
6-
Senility, Dementia and Alzheimer's
7-
Immune Deficiencies
8-
Osteoporosis and Tooth Loss
9-
Hormonal Imbalances and Premature Aging
References:
Reynolds, J.E.F., (ed), Martindale, The Extra
Pharmacopoeia, Royal Pharmaceutical Society, London, 31st Edition,
1996, 981-981.
Grier MT, Meyers, D.G., So much writing, so
little science: a review of 37 years of literature on ededate
sodium chelation therapy, Annuals of Pharmacotherapy, 1993, 18:
1000-3.
Fouque, D., and Kopple, J.D., Total Parenteral
Nutrition and Its Complications, in Arieff, Allen I., and DeFronzo,
Ralph, A., (Editors) Fluid, Electrolyte and Acid-Base Disorders,
Churchill Livingstone, New York, NY, 1995.
Jones, J., Amino Acid and Peptide Synthesis,
Oxford University Press, Oxford, 1992.
Cynober, L.A., Amino Acid Metabolism and Therapy
and Nutritional Disease, CRC Press, Boco Raton, FL., 1995.
Lehninger, A.L., Nelson, D.L. and Cox, M.M.,
Principles of Biochemistry, Worth Publishers, New York, NY, 1993.
Linder, M.C., Editor, Nutritional Biochemistry
and Metabolism with Clinical Applications, Appelton & Lange,
Norwalk, CT, 1991.
Freidman, Mendel, Absorption and Utilization
of Amino Acids, Vol. I,II,III, CRC Press, Boca Raton, FL., 1989.
Patton, K.T., Thibodeau, Gary G., Anatomy &
Physiology, Third Edition, Mosby, St. Louis, MO. 1996.
Weatherall, D.J., Ledingham, J.G.G., Warrell,
D.A., (Editors), Oxford Textbook of Medicine, Volumes 1,2 &
3, Oxford University Press, Oxford, England, 1996.
Windhorst, U., Regulatory Principles in Physiology,
in Greger, R., and Windhorst, U., (Editors), Comprehensive Human
Physiology, Volume 1 & 2, Springer Publishing, New York and
Heidleberg, 1996.
Palamara, A.T., Perno, C.F., Aquaro, S., Bue,
M.C., Dini, L., Garaci, E., Glutathione inhibits HIV replication
by acting at late stages of the virus life cycle. AIDS Res Hum
Retroviruses 1996 Nov 1;12(16):1537-41.
Coronary Heart Disease, Supplement to the Lancet,
Lancet, 348, (suppl I), 1-21, 1996.
Herzenberg, L.A., De Rosa, S.C., Dubs, J.G.,
Roederer, M., Anderson, M.T., Ela, S.W., Deresinski, S.C., Herzenberg,
L.A., Glutathione deficiency is associated with impaired survival
in HIV disease. Proc Natl Acad Sci U S A 1997 Mar 4;94(5):1967-72.
Sachan, A.S., Kannan, G.M., Kumar, P., Flora,
S.J., Effects of chelation therapy on hepatic glutathione, lipid
peroxidation and phospholipid contents in lead-poisoned rats,
Indian J Physiol Pharmacol 1996 Apr;40(2):180-2.
Ali, M.S., Quadri, S.M., Maleimido derivatives
of diethylenetriaminepentaacetic acid and triethylenetetraaminehexaacetic
acid: their synthesis and potential for specific conjugation with
biomolecules, Bioconjug Chem 1996 Sep-Oct;7(5):576-83.
Chappell, L.T., Janson, M., EDTA chelation therapy
in the treatment of vascular disease, J Cardiovasc Nurs 1996 Apr;10(3):78-86,
and comment in: J Cardiovasc Nurs 1996 Apr;10(3):v-x.
Eder, M.I., Miquel, J.F., Jongst, D., Paumgartner,
G., von Ritter, C., Reactive oxygen metabolites promote cholesterol
crystal formation in model bile: role of lipid peroxidation, Free
Radic Biol Med 1996;20(5):743-9.
Tandon, S.K., Singh, S., Flora, S.J., Influence
of methionine and zinc supplementation during chelation of lead
in rats. J Trace Elem Electrolytes Health Dis 1994 Jun;8(2):75-7.
Tandon, S.K., Singh, S., Jain, V.K., Efficacy
of combined chelation in lead intoxication. Chem Res Toxicol 1994
Sep-Oct;7(5):585-9.
Tomita, M., Hayashi, M., Awazu, S., Absorption-enhancing
mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells.J
Pharm Sci 1996 Jun;85(6):608-11.
Janson, M., "Combining Chelation and Nutrition
Therapy for Vascular Disease," 1996 Dec. Nut Science News
|
